erlotinib hydrochloride has been researched along with Intestinal Perforation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Islam, R; Majid, NA; Shah, WS | 1 |
| Gairard-Dory, AC; Gass-Jégu, F; Gourieux, B; Gschwend, A; Mennecier, B; Quoix, É; Tebacher-Alt, M | 1 |
| Cheon, YH; Jeon, DH; Kang, MG; Kim, CY; Kim, HJ; Kim, MJ; Kim, YE; Lee, GW; Lee, SS | 1 |
1 review(s) available for erlotinib hydrochloride and Intestinal Perforation
| Article | Year |
|---|---|
Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Intestinal Perforation; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Radiography, Thoracic; Stomach Diseases; Tomography, X-Ray Computed | 2016 |
2 other study(ies) available for erlotinib hydrochloride and Intestinal Perforation
| Article | Year |
|---|---|
Duodenal Perforation Secondary to Erlotinib Therapy in a Patient With Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Duodenum; Erlotinib Hydrochloride; Female; Humans; Intestinal Perforation; Lung Neoplasms; Middle Aged; Risk Factors | 2017 |
Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Intestinal Fistula; Intestinal Perforation; Protein Kinase Inhibitors; Quinazolines; Radiography; Sigmoid Diseases | 2011 |